FindTrial
Sign In

PTG-300

DRUG6 trials

Sponsors

Protagonist Therapeutics, Inc.

Conditions

Chronic AnemiaHealthy VolunteersHereditary HemochromatosisIneffective ErythropoiesisPolycythemia Veraβ-thalassemia

Phase 1

Pharmacokinetics and Pharmacodynamics of Different PTG-300 Regimens in Healthy Volunteers
CompletedNCT04516382
Protagonist Therapeutics, Inc.Healthy Volunteers
Start: 2020-09-14End: 2021-06-30Updated: 2021-09-16

Phase 2

Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia
CompletedNCT03802201
Protagonist Therapeutics, Inc.Chronic Anemia, Ineffective Erythropoiesis, β-thalassemia
Start: 2018-12-19End: 2020-07-31Updated: 2021-07-16
Safety Study for Beta Thalassemia Subjects on PTG-300
CompletedNCT04054921
Protagonist Therapeutics, Inc.Ineffective Erythropoiesis, β-thalassemia
Start: 2019-05-10End: 2020-07-31Updated: 2021-07-16
Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)
CompletedNCT04057040
Protagonist Therapeutics, Inc.Polycythemia Vera
Start: 2019-10-01End: 2024-06-17Updated: 2025-08-07
PTG-300 in Subjects With Hereditary Hemochromatosis
CompletedNCT04202965
Protagonist Therapeutics, Inc.Hereditary Hemochromatosis
Start: 2020-03-19End: 2022-02-15Updated: 2025-08-20
PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit
CompletedNCT04767802
Protagonist Therapeutics, Inc.Polycythemia Vera
Start: 2021-02-02End: 2023-03-15Updated: 2024-03-18

Related Papers

Long-term rusfertide treatment in polycythemia vera: Initial results from the phase 2 THRIVE extension study
Blood2025-11-03
Final Results from the Phase 2 Revive Study Investigating the Hepcidin Mimetic Rusfertide in Patients with Polycythemia Vera (PV)
Blood2024-11-052 citations
VERIFY: A randomized controlled phase 3 study of the hepcidin mimetic rusfertide (PTG-300) in patients with polycythemia vera (PV).
Journal of Clinical Oncology2024-06-013 citations
Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera
New England Journal of Medicine2024-02-2137 citations
Durability of Hematocrit Control in Polycythemia Vera with the First-in-Class Hepcidin Mimetic Rusfertide: Two-Year Follow up Results from the Revive Study
Blood2023-11-024 citations
Rusfertide Improves Markers of Iron Deficiency in Patients with Polycythemia Vera
Blood2023-11-021 citations
Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial.
2023-10-1721 citations
P1016: RUSFERTIDE (PTG-300) IMPROVES POLYCYTHEMIA VERA (PV) RELATED SYMPTOMS IN PV PATIENTS
HemaSphere2023-08-012 citations
P1048: PHARMACOKINETIC AND PHARMACODYNAMIC EFFECTS OF RUSFERTIDE IN POLYCYTHEMIA VERA: RESULTS FROM AN ONGOING PHASE 2 STUDY IN PATIENTS WITH ELEVATED HEMATOCRIT VALUES
HemaSphere2023-08-01
Hepcidin mimetics in polycythemia vera: resolving the irony of iron deficiency and erythrocytosis.
2022-12-2916 citations
Verify: A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera
Blood2022-11-157 citations
Rusfertide for Polycythemia Vera: Similar Dosing in Patients Receiving Therapeutic Phlebotomy Alone or in Combination with Cytoreductive Treatment
Blood2022-11-154 citations
Subgroup Analysis of Adverse Events Following Rusfertide Dosing in Revive: A Phase 2 Study of Patients with Polycythemia Vera
Blood2022-11-151 citations
Rusfertide (PTG-300) treatment in phlebotomy-dependent polycythemia vera patients.
Journal of Clinical Oncology2022-06-0120 citations
P1028: PTG-300 (RUSFERTIDE) TREATMENT INTERRUPTION REVERSES HEMATOLOGICAL GAINS AND RESTORES THERAPEUTIC BENEFIT ON REINITIATION IN SUBJECTS WITH POLYCYTHEMIA VERA
HemaSphere2022-06-011 citations